Department of Epidemiology and Biostatistics, University of California, San Francisco.
now at Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison.
JAMA Netw Open. 2020 Nov 2;3(11):e2025515. doi: 10.1001/jamanetworkopen.2020.25515.
Observational studies consistently report inverse associations between cancer and Alzheimer disease (AD). Shared inverse etiological mechanisms might explain this phenomenon, but a systematic evaluation of methodological biases in existing studies is needed.
To systematically review and meta-analyze evidence on the association between cancer and subsequent AD, systematically identify potential methodological biases in studies, and estimate the influence of these biases on the estimated pooled association between cancer and AD.
All-language publications were identified from PubMed, Embase, and PsycINFO databases through September 2, 2020.
Longitudinal cohort studies and case-control studies on the risk of AD in older adults with a history of any cancer type, prostate cancer, breast cancer, colorectal cancer, or nonmelanoma skin cancer, relative to those with no cancer history.
Two reviewers independently abstracted the data and evaluated study biases related to confounding, diagnostic bias, competing risks, or survival bias. Random-effects meta-analysis was used to provide pooled estimates of the association between cancer and AD. Metaregressions were used to evaluate whether the observed pooled estimate could be attributable to each bias. The study was designed and conducted according to the Preferring Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.
Incidence, hazard, or odds ratios for AD comparing older adults with vs without a previous cancer diagnosis.
In total, 19 cohort studies and 3 case-control studies of the associations between any cancer type (n = 13), prostate cancer (n = 5), breast cancer (n = 1), and nonmelanoma skin cancer (n = 3) with AD were identified, representing 9 630 435 individuals. In all studies combined, cancer was associated with decreased AD incidence (cohort studies: random-effects hazard ratio, 0.89; 95% CI, 0.79-1.00; case-control studies: random-effects odds ratio, 0.75; 95% CI, 0.61-0.93). Studies with insufficient or inappropriate confounder control or greater likelihood of AD diagnostic bias had mean hazard ratios closer to the null value, indicating that these biases could not explain the observed inverse association. Competing risks bias was rare. Studies with greater likelihood of survival bias had mean hazard ratios farther from the null value.
The weak inverse association between cancer and AD may reflect shared inverse etiological mechanisms or survival bias but is not likely attributable to diagnostic bias, competing risks bias, or insufficient or inappropriate control for potential confounding factors.
观察性研究一致报告癌症与阿尔茨海默病(AD)之间呈负相关。共同的病因学机制可能解释了这一现象,但需要系统评估现有研究中的方法学偏倚。
系统回顾和荟萃分析癌症与随后发生 AD 之间关联的证据,系统识别研究中潜在的方法学偏倚,并估计这些偏倚对癌症与 AD 之间估计的汇总关联的影响。
通过 2020 年 9 月 2 日在 PubMed、Embase 和 PsycINFO 数据库中检索所有语言的出版物。
对有任何癌症类型、前列腺癌、乳腺癌、结直肠癌或非黑色素瘤皮肤癌病史的老年人群中 AD 风险的纵向队列研究和病例对照研究,与无癌症史的人群进行比较。
两位审阅者独立提取数据,并评估与混杂、诊断偏差、竞争风险或生存偏差相关的研究偏倚。使用随机效应荟萃分析提供癌症与 AD 之间关联的汇总估计。进行元回归以评估观察到的汇总估计值是否归因于每个偏倚。该研究根据系统评价和荟萃分析的首选报告项目(PRISMA)报告准则进行设计和开展。
比较有和无既往癌症诊断的老年人 AD 的发生率、风险比或优势比。
共纳入了 19 项关于任何癌症类型(n=13)、前列腺癌(n=5)、乳腺癌(n=1)和非黑色素瘤皮肤癌(n=3)与 AD 关联的队列研究和 3 项病例对照研究,共纳入 9630435 人。综合所有研究,癌症与 AD 发生率降低相关(队列研究:随机效应风险比,0.89;95%CI,0.79-1.00;病例对照研究:随机效应优势比,0.75;95%CI,0.61-0.93)。控制混杂因素不足或不适当或 AD 诊断偏差可能性较大的研究的平均风险比更接近零值,表明这些偏倚不能解释观察到的负相关。竞争风险偏倚很少见。生存偏差可能性较大的研究的平均风险比离零值更远。
癌症与 AD 之间的弱负相关可能反映了共同的病因学机制或生存偏差,但不太可能归因于诊断偏差、竞争风险偏差或对潜在混杂因素控制不足或不适当。